These findings highlight the importance of considering tissue-specific expression, disease stage and treatment context when evaluating DPP4-targeted therapies in prostate cancer, as their efficacy appears closely tied to the unique biology of this tumor type (Russo et al., 2018; Shah et al., 2019; Mangoura et al., 2024). Here, DPP4 is linked to neoplasm.